Systems Thinking & Decision Flows
Untangling Prior Authorization
This started as a simple system-mapping exercise.
I've since researched it and built it out further, because access to quality healthcare and cost transparency are passions of mine for a healthier, more equitable society.
Overview
Prior authorization is meant to give patients and providers fast confidence that treatment will be covered. Mapping it as a system showed that the real failure point is the payer-to-provider decision, not the patient's experience of it.
| Type | Concept case study, MIT xPRO Systems Thinking |
|---|---|
| My role | Systems analyst and author; a personal care experience first prompted the analysis |
| Domain | Healthcare: payers, providers, patients |
| Methods | Emergent function and "ilities" analysis; entity-pair structure and interaction grid |
| Outcome | Four system-level recommendations, checked against published evidence |
The Problem
When my family needed urgent rabies vaccine treatment, we agreed to it without any clarity about coverage or cost. That uncertainty led me to learn how insurers decide coverage, and to prior authorization, which fails in far higher-stakes cases such as cancer treatment or experimental drugs that can cost hundreds of thousands of dollars.
In prior authorization, a provider must ask the insurer (the payer) to confirm a treatment is "medically necessary" before administering it, so the provider knows it will be reimbursed. The patient waits in between, often with little visibility into status or cost.
Approach
I started from what the system is supposed to produce, then worked backward to where it fails. The expected emergent function is simple: patient and provider get timely confirmation that treatment will be covered.
I then looked at how that function breaks down, using systems-thinking "ilities":
| Lens | How the system fails | Effect on the patient |
|---|---|---|
| Performance | The payer delays processing the provider's request | Delay can conflict with urgent need for treatment and cause harm |
| Reliability | Treatments considered experimental may be denied | Harm from going without, or financial hardship from paying |
| Emergency | The payer's system doesn't function properly | An expensive, urgent treatment becomes an emergency for the patient |
System map and decision flow
Each lane is a role from the map, and the path shows how one request moves between them, including what happens after a denial.
One payer decision determines whether care happens on time
My system map as a decision flow by role; appeal figures from KFF (Medicare Advantage, 2024)
Swipe sideways to see the full flow.
The payer's medical-necessity decision is the hinge. A yes moves care forward; a no sends the patient onto an appeal path most people never take. Not every unappealed denial means care was forgone, but each one adds delay or cost for the patient.
Process Flow
I mapped each pair of entities by its structure (connection or sequence) and its interaction (what passes between them). Four entities and six interactions make up the core loop.
Prior authorization breaks at the payer decision back to the provider
Swipe sideways to see the full flow.
Each line is one pair from my structure-and-interaction grid. The highlighted line, the payer's decision back to the provider, is where delays emerge.
Insight: where the system breaks
The system fails at one interaction: the payer's decision back to the provider. Proper functioning looks like expedited access to treatment for the patient, and that depends on the payer rendering a timely decision.
That makes this a performance and reliability dependency between two organizations, not a patient-experience problem. A better patient-facing screen wouldn't help if the decision itself is slow or unpredictable.
Population health impact
For patients and providers, prior authorization stands between a clinical decision and timely care. In a recent AMA survey of 1,000 physicians, 93% said it delays care and 29% said it led to a serious adverse event for a patient (AMA). Among cancer patients who faced delays, 73% waited two weeks or longer, and delays came with more anxiety and more paperwork for patients themselves (JAMA Network Open). Physicians report it takes the equivalent of 12 hours of physician and staff time each week, time not spent with patients (AMA).
Repeated across millions of people, the delay becomes a filter on care. In Medicare Advantage in 2024, insurers denied 4.1 million of nearly 53 million requests. Only 11.5% of denials were appealed, and 80.7% of appeals overturned the denial (KFF), so many patients who didn't appeal likely went without care that would have been approved.
Insurers argue that prior authorization prevents unnecessary or unsafe care and keeps premiums down, and that argument deserves a fair hearing. But the evidence shows the cost of a slow, unclear decision lands on the people with the least room to wait: a patient who needs treatment now, and a provider trying to deliver quality care. Removing review alone isn't the answer either. When 23 state Medicaid programs dropped it for buprenorphine, prescribing rose only in states that started low (JAMA Health Forum). The goal is a decision that is fast, clear and visible to the patient and provider.
| Effect | Evidence |
|---|---|
| Treatment interruption | Adding prior authorization to an oral cancer drug patients were already taking made them 7.1 times more likely to stop it within 120 days (Harvard Medical School) |
| Missed recommended care | 22% of surveyed cancer patients didn't receive recommended care because of prior authorization; 69% had delays (JAMA Network Open) |
| Slower public health gains | Easing Medicaid hepatitis C restrictions added 966 treatment courses per 100,000 beneficiaries per quarter (JAMA Health Forum) |
| Unequal burden | Medicaid managed care plans denied 1 in 8 requests in 2019, with little state review (HHS OIG) |
| Shifted costs | Drug prior authorization costs an estimated $93.3 billion a year, $35.8 billion of it borne by patients (Health Affairs, via AMA) |
Recommendations
My original map pointed to the first two changes;
the research added two more. The patient is experiencing downstream affects of policy and operations decisions.
Clearer coverage policy criteria. If providers know up front what payers will cover, they can recommend treatments likely to be approved, reducing denials and back-and-forth.
Faster payer decisions. Shortening the time to a decision improves both the speed and the quality of treatment from provider to patient.
Evidence: since 2026, CMS requires decisions within 72 hours for urgent requests and 7 days for standard ones (CMS); physician groups pushed for 24 and 48 hours.
Patient visibility into status and cost. Show patients where their request stands, what is still needed and what they may owe, so they aren't left waiting in the dark.
Evidence: one in three insured adults name prior authorization as the single biggest burden in getting care, beyond cost (KFF).
Fewer, smarter requests. Remove review where approvals are near-universal, and design exemptions that providers can realistically earn.
Evidence: plans report eliminating 11% of prior authorizations since their 2025 pledge (BCBSA), but only 3% of Texas clinicians qualified for the state's "gold card" exemption (Texas Medical Association).